You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemia
SBC: MICROFLUIDIC INNOVATIONS, LLC Topic: 102DESCRIPTION provided by applicant Kinase inhibitors created a new paradigm in chemotherapy and are a major focus of new oncology drug development The Bcr Abl inhibitor imatinib was a breakthrough drug for chronic myelogenous leukemia with overwhelming early results however at least of patients are either intolerant resistant or experience recurrence within years and individual respo ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Accurate Protein Identification using Peptide Separation Information and Tandem M
SBC: PREDICTIVE PHYSIOLOGY AND MEDICINE, INC. Topic: N/ADESCRIPTION (provided by applicant): A significant problem currently hindering proteomics studies is the identification of peptides and proteins from mass spectral data. This problem is manifest in the difficulty to establish confidence limits of protein a nd peptide identifications. A serious concern is the tendency for the occurrence of false positive assignments. The development of an integrate ...
STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Acne Vaccines Targeting a Surface Sialidase and a Secreted CAMP Factor Toxin
SBC: VAXIN INC. Topic: N/ADESCRIPTION (provided by applicant): Propionibacterium acnes (P. acnes) is most notably recognized for its role in acne vulgaris, the most common skin disease, affecting 85-100% of the population at some point in their lives. Current treatments for vulgari s acne using isotretinoin (13-cis-retinoic acid) or antibiotics can have many undesirable effects, including depression, teratogenicity, hormon ...
STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Acute-infarct selective cardiac MRI contrast agent
SBC: ELGAVISH PARAMAGNETICS, INC. Topic: N/ADESCRIPTION (provided by applicant): Reliable diagnostic differentiation between acute and chronic myocardial infarcts would be of great benefit for cardiac surgeons and interventional cardiologists. Such differentiation could be used to make decisions about which vessels and in what order would be reopened or bypassed. MRI is an intrinsically noninvasive diagnostic tool and the Delayed Enhancemen ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Acute-infarct selective cardiac MRI contrast agent
SBC: ELGAVISH PARAMAGNETICS, INC. Topic: NHLBIDESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Adenovirus vectored vaccines for Alzheimer's disease
SBC: VAXIN INC. Topic: N/ADESCRIPTION (provided by applicant): Alzheimer disease (AD) is the most common neurodegenerative disease in the elderly. To date, no satisfactory treatment is available for AD. One of the pathological hallmarks of AD is deposits of amyloid protein (Aa) in neuritic plaques and cerebral vessels. Increasing lines of evidence support the notion that Aa and its precursor (APP) play pathogenetic roles i ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
A device containing an immobilized chelator to remove aluminum from total parente
SBC: ALKYMOS, INC Topic: NICHDDESCRIPTION (provided by applicant): A high percentage of the ~ 500,000 children born prematurely each year in the US require intravenous feeding after birth because they do not tolerate oral feeding. This is accomplished with a total parenteral nutrition (TPN) solution, which is prepared from component solutions: small and large volume parenterals (SVPs and LVPs). Aluminum (Al) is a common contam ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
A device containing immobilized chelator to remove aluminum from TPN solutions
SBC: ALKYMOS, INC Topic: N/ADESCRIPTION (provided by applicant): A high percentage of the ~ 470,000 children born prematurely each year in the US require intravenous feeding after birth because they do not tolerate oral feeding. This is accomplished with a total parenteral nutrition (TPN) solution, which is prepared from component solutions: small and large volume parenterals (SVPs and LVPs). Aluminum (Al) is a common conta ...
STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Alpha-1 Antitrypsin Gene Therapy for Cystic Fibrosis
SBC: Generx+, Inc. Topic: N/ADESCRIPTION (Applicant's Abstract): The investigators have developed a plasmid vector that expresses the normal human alpha-1 antitrypsin (AAT) gene in human respiratory epithelium when delivered as a plasmid-cationic liposome complex. In subjects with inherited AAT deficiency, they showed that liposome mediated transfer of the normal AAT gene to the nasal respiratory epi ...
STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health -
AMD-FCRx to Restore Damaged Pigment Epithelium
SBC: REGENEREX, LLC Topic: N/ADESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is the leading cause of blindness in the Western world. The hallmark of the disease is retinal pigment epithelial (RPE) dysfunction with subsequent death of the foveal photoreceptors. Hematopoietic stem cells (HSC) have been demonstrated to repair damaged tissues including heart muscle and nerve under selected conditions. ...
STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health